Production (Stage)
Calidi Biotherapeutics, Inc.
CLDI
$0.31
-$0.01-3.13%
AMEX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -4.99M | -4.10M | -5.05M | -5.77M | -7.23M |
| Total Depreciation and Amortization | 394.00K | 393.00K | 390.00K | 378.00K | 374.00K |
| Total Amortization of Deferred Charges | -- | 4.00K | 9.00K | 16.00K | 16.00K |
| Total Other Non-Cash Items | 496.00K | 527.00K | 297.00K | 656.00K | 1.09M |
| Change in Net Operating Assets | -3.04M | -2.25M | -588.00K | -777.00K | 1.92M |
| Cash from Operations | -7.13M | -5.42M | -4.95M | -5.49M | -3.83M |
| Capital Expenditure | -7.00K | -5.00K | -6.00K | 0.00 | -5.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -7.00K | -5.00K | -6.00K | 0.00 | -5.00K |
| Total Debt Issued | -- | 0.00 | 600.00K | 0.00 | 3.20M |
| Total Debt Repaid | -1.67M | -19.00K | -18.00K | -1.82M | -23.00K |
| Issuance of Common Stock | 10.08M | 13.63M | 3.74M | 5.51M | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -301.00K | -502.00K | 1.73M | 1.51M | -164.00K |
| Cash from Financing | 8.11M | 13.11M | 6.05M | 5.20M | 3.01M |
| Foreign Exchange rate Adjustments | -- | 16.00K | -33.00K | -13.00K | 17.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 970.00K | 7.69M | 1.06M | -307.00K | -806.00K |